MedTrace Logo

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

NCT00564057 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-12-06

No results posted yet for this study

Summary

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.

Conditions

Interventions

DRUG

candesartan

tablet 8-16 mg once daily, one year

DRUG

lercanidipine

tablets 10-20 mg once daily, one year

Sponsors & Collaborators

  • Università degli Studi dell'Insubria

    lead OTHER

Principal Investigators

  • anna maria grandi, MD · University of Insubria, Varese, ITALY

  • paolo grossi, MD · University of Insubria, Varese, Italy

  • andrea maria maresca, MD · University of Insubria, Varese, Italy

  • eleonora nicolini, MD · University of Insubria, Varese, Italy

  • massimo giola, MD · University of Insubria, Varese, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2009-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564057 on ClinicalTrials.gov